a Aarhus Universitet Hospital, Department of Surgery , Aarhus , Denmark.
b Charite Campus Mitte, Surgery , Berlin , Germany.
Int J Hyperthermia. 2017 Aug;33(5):528-533. doi: 10.1080/02656736.2017.1315178.
The treatment of peritoneal surface malignancies ranges from palliative care to full cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy, HIPEC. Ongoing monitoring of patient recruitment and volume is usually carried out through dedicated registries. With multiple registries available worldwide, we sought to investigate the nature, extent and value of existing worldwide CRS and HIPEC registries.
A questionnaire was sent out to all known major treatment centres. The questionnaire covers: general purpose of the registry; inclusion criteria in the registry; the date the registry was first established; volume of patients in the registry and description of the data fields in the registries. Finally, the population size of the catchment area of the registry was collected.
Twenty-seven questionnaires where returned. National databases are established in northwest European countries. There are five international general databases. Most database collect data on patients who have undergone an attempt to CRS and HIPEC. Two registries collect data on all patients with peritoneal carcinomatosis regardless the treatment. Most registries are primarily used for tracking outcomes and complications. When correlating the number of cases of CRS and HIPEC that are performed to the catchment area of the various registry, a large variation in the number of performed procedures related to the overall population was noted, ranging from 1.3 to 57 patients/million year with an average of 15 patients/1 million year.
CRS and HIPEC is a well-established treatment for peritoneal surface malignancies worldwide. However, the coverage as well as the registration of treatment procedures differs widely. The most striking difference is the proportion of HIPEC procedures per capita which ranges from 1.3 to 57 patients per million. This suggests either a difference in patient selection, lack of access to HIPEC centres or lack of appropriate data collection.
腹膜表面恶性肿瘤的治疗范围从姑息治疗到完全细胞减灭术(CRS)和加热腹腔内化疗(HIPEC)。通常通过专门的登记处对患者招募和数量进行持续监测。随着全球多个登记处的出现,我们旨在调查全球现有的 CRS 和 HIPEC 登记处的性质、范围和价值。
向所有已知的主要治疗中心发送了一份问卷。问卷涵盖:登记处的一般用途;登记处的纳入标准;登记处首次建立的日期;登记处的患者数量以及登记处的数据字段描述。最后,还收集了登记处的集水区的人口规模。
共收回 27 份问卷。西北欧国家建立了国家数据库。有五个国际通用数据库。大多数数据库收集接受过 CRS 和 HIPEC 尝试治疗的患者的数据。有两个登记处收集所有患有腹膜癌病的患者的数据,无论治疗方法如何。大多数登记处主要用于跟踪结果和并发症。当将 CRS 和 HIPEC 的病例数与各个登记处的集水区相关联时,注意到与总人口相关的手术数量存在很大差异,范围从每百万人口 1.3 例至 57 例,平均每百万人口 15 例。
CRS 和 HIPEC 是全球腹膜表面恶性肿瘤的成熟治疗方法。然而,治疗程序的覆盖范围和登记情况差异很大。最显著的差异是人均 HIPEC 手术比例,范围从每百万人口 1.3 例至 57 例。这表明存在患者选择差异、缺乏 HIPEC 中心的机会或缺乏适当的数据收集。